N-terminally fusion of Her2/neu to HSP70 decreases efficiency of Her2/neu DNA vaccine

Cell Stress and Chaperones

Volumn 15, Issue 5, 2010, Pages 631-638

  Pakravan, Nafiseh ^a   Soudi, Sara ^a   Hassan, Zuhair Mohammad ^a  

^a TARBIAT MODARES UNIVERSITY   (Iran)

Author keywords

Biologic adjuvant; Her2; HSP70; Regulatory T cells

Indexed keywords

CD4 ANTIGEN; DNA VACCINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; HEAT SHOCK PROTEIN 70; INTERLEUKIN 2 RECEPTOR ALPHA; MEMBRANE PROTEIN; SCLEROPROTEIN; TRANSCRIPTION FACTOR FOXP3;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN EXPRESSION; ARTICLE; CANCER IMMUNIZATION; CANCER IMMUNOTHERAPY; CD4 CD8 RATIO; CELL PROLIFERATION; CONTROLLED STUDY; CYTOTOXICITY; FEMALE; IMMUNE RESPONSE; IMMUNOREACTIVITY; LYMPHOCYTE SUBPOPULATION; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; T LYMPHOCYTE; TUMOR; TUMOR GROWTH;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; FEMALE; FLOW CYTOMETRY; HSP70 HEAT-SHOCK PROTEINS; INTERFERON-GAMMA; INTERLEUKIN-4; MICE; MICE, INBRED BALB C; RECEPTOR, ERBB-2; RECOMBINANT FUSION PROTEINS; VACCINES, DNA;

MUS; RATTUS;

EID: 77955712095     PISSN: 13558145     EISSN: 14661268     Source Type: Journal    
DOI: 10.1007/s12192-010-0175-0     Document Type: Article

References (49)

1. A Amici FM Venanzi A Concetti 1998 Genetic immunization against neu/erbB2 transgenic breast cancer Cancer Immunol Immunother 47 183 190 10.1007/s002620050519 1:CAS:528:DyaK1MXmslSmtw%3D%3D 9875670
2. C Blank I Brown AC Peterson M Spiotto Y Iwai T Honjo, et al. 2004 PD-L1/B7-H1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD81 T cells Cancer Res 64 1140 1145 10.1158/0008-5472.CAN-03- 3259 1:CAS:528:DC%2BD2cXhtFCgtrs%3D 14871849
3. CN Baxevanis PA Sotiropoulou NN Sotiriadou M Papamichail 2004 Immunobiology of HER-2/neu oncoprotein and its potential application in cancer immunotherapy Cancer Immunol Immunother 53 3 166 175 10.1007/s00262-003-0475-7 1:CAS:528:DC%2BD2cXhtlehsLY%3D 14685781
4. JS Boyle JL Brady C Koniaras AM Lew 1998 Inhibitory effect of lipopolysaccharide on immune response after DNA immunization is route dependent DNA Cell Biol 17 4 343 348 10.1089/dna.1998.17.343 1:CAS:528:DyaK1cXivFCmsr4%3D 9570151
5. C Castelli L Rivoltini F Rini F Belli A Testori M Maio, et al. 2004 Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer Cancer Immunol Immunother 53 227 233 10.1007/s00262-003-0481-9 1:CAS:528:DC%2BD2cXhtlehsLc%3D 14689240
6. + T cell response to repetitive stimulation with antigen-presenting cells in vitro: implications in designing antigen-presenting cell-based tumor vaccines J Immunol 162 5576 5583 1:CAS:528:DyaK1MXislGnsb8%3D 10228040
7. CH Chen TL Wang CF Hung Y Yang RA Young DM Pardoll, et al. 2000 Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene Cancer Res 60 4 1035 1042 1:CAS:528:DC%2BD3cXhs1ShsL0%3D 10706121
8. C Curcio E Di Carlo R Clynes MJ Smyth K Boggio E Quaglino, et al. 2003 Nonredundant roles of antibody, cytokines, and perforin in the eradication of established Her-2/neu carcinomas J Clin Invest 111 1161 1170 1:CAS:528:DC%2BD3sXjtFCrs74%3D 12697735
9. TJ Curier G Coukos LH Zou X Alvarez P Cheng P Mottram, et al. 2004 Specific recruitment of regulatory T cells in ovarian carcinoma fosters privilege and predicts reduced survival Nat Med 10 942 949 10.1038/nm1093
10. H Geng GM Zhang H Xiao Y Yuan D Li H Zhang, et al. 2006 HSP70 vaccine in combination with gene therapy with plasmid DNA encoding sPD-1 overcomes immune resistance and suppresses the progression of pulmonary metastatic melanoma Int J Cancer 118 11 2657 2664 10.1002/ijc.21795 1:CAS:528:DC%2BD28Xks1Sisrk%3D 16425224
11. NF Gordon BL Clark 2004 The challenges of bringing autologous HSP-based vaccines to commercial reality Methods 32 63 69 10.1016/S1046-2023(03)00188-9 1:CAS:528:DC%2BD3sXptVersLY%3D 14624879
12. SM Hashemi ZM Hassan S Soudi T Ghazanfari M Kheirandish S Shahabi 2007 Evaluation of anti-tumor effects of tumor cell lysate enriched by HSP-70 against fibrosarcoma tumor in BALB/c mice Int Immunopharmacol 7 7 920 927 10.1016/j.intimp.2007.02.013 1:CAS:528:DC%2BD2sXlt1aksL8%3D 17499194
13. YF He XH Wang GM Zhang HT Chen H Zhang ZH Feng 2005 Sustained low-level expression of interferon-g promotes tumor development: potential insights in tumor prevention and tumor immunotherapy Cancer Immunol Immunother 54 891 897 10.1007/s00262-004-0654-1 1:CAS:528:DC%2BD2MXlvVynsrk%3D 15776283
14. F Hirano K Kaneko H Tamura H Dong S Wang M Ichikawa, et al. 2005 Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity Cancer Res 65 1089 1096 1:CAS:528:DC%2BD2MXhtVWnurg%3D 15705911
15. KF Hsu CF Hung WF Cheng L He LA Slater M Ling, et al. 2001 Enhancement of suicidal DNA vaccine potency by linking Mycobacterium tuberculosis heat shock protein 70 to an antigen Gene Ther 8 5 376 383 10.1038/sj.gt.3301408 1:CAS:528:DC%2BD3MXhvVKks70%3D 11313814
16. H Jiang L Chess 2009 How the immune system achieves self-nonself discrimination during adaptive immunity Adv Immunol 102 95 133 10.1016/S0065-2776(09)01202-4 1:CAS:528:DC%2BD1MXhtVSnsbjP 19477320
17. JH Kim N Majumder H Lin J Chen LD Falo Jr Z You 2005 Enhanced immunity by NeuEDhsp70 DNA vaccine is needed to combat an aggressive spontaneous metastatic breast cancer Mol Ther 11 6 941 949 10.1016/j.ymthe.2005.01.003 1:CAS:528:DC%2BD2MXks1ajsbc%3D 15922965
18. M Kmieciak KL Knutson CI Dumur MH Manjili 2007 HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses Eur J Immunol 37 3 675 685 10.1002/eji.200636639 1:CAS:528:DC%2BD2sXjs1Sjsbo%3D 17304628
19. SL Kominsky AC Hobeika FA Lake BA Torres HM Johnson 2000 Down-regulation of neu/HER-2 by interferon-γ in prostate cancer cells Cancer Res 60 14 3904 3908 1:CAS:528:DC%2BD3cXlt1GktLY%3D 10919667
20. SL Kominsky AC Hobeika FA Lake BA Torres HM Johnson 2000 Down-regulation of neu/HER-2 by interferon-γ in prostate cancer cells Cancer Res 60 3904 3908 1:CAS:528:DC%2BD3cXlt1GktLY%3D 10919667
21. YH Lan YG Li ZW Liang M Chen ML Peng L Tang, et al. 2007 A DNA vaccine against chimeric AFP enhanced by HSP70 suppresses growth of hepatocellular carcinoma Cancer Immunol Immunother 56 7 1009 1016 10.1007/s00262-006-0254-3 1:CAS:528:DC%2BD2sXks1agsbg%3D 17186291
22. AP Lepique K Regina P Daghastanli IM Cuccovia LL Villa 2009 HPV16 tumor associated macrophages suppress antitumor T cell responses Clin Cancer Res 15 13 4391 4400 10.1158/1078-0432.CCR-09-0489 1:CAS:528:DC%2BD1MXnvFajtr0%3D 19549768
23. Y Li J Subjeck G Yang E Repasky XY Wang 2006 Generation of anti-tumor immunity using mammalian heat shock protein 70 DNA vaccines for cancer immunotherapy Vaccine 24 25 5360 5370 10.1016/j.vaccine.2006.04.028 1:CAS:528:DC%2BD28Xltlemsrw%3D 16714072
24. H Li X Ou J Xiong 2007 Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules Gynecol Oncol 104 3 564 571 10.1016/j.ygyno.2006.09.027 1:CAS:528:DC%2BD2sXitFOgsLo%3D 17081598
25. CC Lin CW Chou AL Shiau CF Tu TM Ko YL Chen, et al. 2004 Therapeutic HER2/Neu DNA vaccine inhibits mouse tumor naturally over expressing endogenous neu Mol Ther 10 2 290 301 10.1016/j.ymthe.2004.05.015 1:CAS:528: DC%2BD2cXmt1Cms70%3D 15294176
26. S Lindquist 1985 The heat-shock response Ann Rev Biochem 55 1151 1191 10.1146/annurev.bi.55.070186.005443
27. A Liso R Benedetti M Fagioli A Mariano B Falini 2005 Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma Haematologica 90 1 60 65 1:CAS:528:DC%2BD2MXhvFGjsLk%3D 15642670
28. JH Ma YF Sui J Ye YY Huang ZS Li GS Chen, et al. 2005 Heat shock protein 70/MAGE-3 fusion protein vaccine can enhance cellular and humoral immune responses to MAGE-3 in vivo Cancer Immunol Immunother 54 9 907 914 10.1007/s00262-004-0660-3 1:CAS:528:DC%2BD2MXlvVynsr0%3D 15756604
29. Y Nagata R Furugen A Hiasa H Ikeda N Ohta K Furukawa, et al. 1997 Peptides derived from a wild-type murine protooncogene c-erbB-2/HER2/2 neu can induce CTL and tumor suppression in syngeneic hosts J Immunol 159 1336 1343 1:CAS:528:DyaK2sXkslKntLw%3D 9233630
30. M Pavlenko AK Roos C Leder LO Hansson R Kiessling E Levitskaya, et al. 2004 Comparison of PSA-specific CD8+ CTL responses and antitumor immunity generated by plasmid DNA vaccines encoding PSA-HSP chimeric proteins Cancer Immunol Immunother 53 12 1085 1092 10.1007/s00262-004-0559-z 1:CAS:528:DC%2BD2cXotlKgtrs%3D 15696608
31. MP Piechocki SA Pilon WZ Wei 2001 Complementary antitumor immunity induced by plasmid DNA encoding secreted and cytoplasmic human erbb-2 J Immunol 167 3367 3374 1:CAS:528:DC%2BD3MXmvFGiur8%3D 11544327
32. E Quaglino C Mastini M Iezzi MP ForniG LN Klapper, et al. 2005 The adjuvant activity of BAT antibody enables DNA vaccination to inhibit the progression of established autochthonous Her-2/neu carcinomas in BALB/c mice Vaccine 23 25 3280 3287 10.1016/j.vaccine.2005.01.086 1:CAS:528: DC%2BD2MXjtlaitLk%3D 15837233
33. S Rolla C Marchini S Malinarich E Quaglino S Lanzardo M Montani, et al. 2008 Protective immunity against neu-positive carcinomas elicited by electroporation of plasmids encoding decreasing fragments of rat neu extracellular domain Hum Gene Ther 19 3 229 240 10.1089/hum.2006.196 1:CAS:528:DC%2BD1cXjs1ejsbY%3D 18269312
34. S Rovero A Amici ED Carlo R Bei P Nanni E Quaglino, et al. 2000 DNA vaccination against rat Her-2/neu p185 more effectively inhibits carcinogenesis than transplantable carcinomas in transgenic BALB/c mice J Immunol 165 9 5133 5142 1:CAS:528:DC%2BD3cXnvVOntr8%3D 11046045
35. Sambrook J, Russell DW (2001) Molecular cloning: a laboratory manual, 3rd edn. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 1.38-1.41, & 1.59-1.61
36. T Schuler Z Qin S Ibe N Noben-Trauth T Blankenstein 1999 T helper cell type 1-associated and cytotoxic T lymphocyte-mediated tumor immunity is impaired in interleukin 4-deficient mice J Exp Med 189 803 810 10.1084/jem.189.5.803 1:CAS:528:DyaK1MXhsF2ju78%3D 10049944
37. EM Shevach 2006 From vanilla to 28 flavors: multiple varieties of T regulatory cells Immunity 25 195 201 10.1016/j.immuni.2006.08.003 1:CAS:528:DC%2BD28XpvVCqu7k%3D 16920638
38. FM Spoelstra DS Postma H Hovenga JA Noordhoek HF Kauffman 1999 Interferon-gamma and interleukin-4 differentially regulate ICAM-1 and VCAM-1 expression on human lung fibroblasts Eur Respir J 14 759 766 10.1034/j.1399-3003.1999.14d06.x 1:CAS:528:DyaK1MXnvVaqsbc%3D 10573217
39. P Srivastava 2002 Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses Annu Rev Immunol 20 395 425 10.1146/annurev.immunol.20.100301.064801 1:CAS:528:DC%2BD38XjtlWgtLo%3D 11861608
40. MH Thornhill SM Wellicome DL Mahiouz JS Lanchbury U Kyan-Aung DO Haskard 1991 Tumor necrosis factor combines with IL-4 or IFN-gamma to selectively enhance endothelial cell adhesiveness for T cells. The contribution of vascular cell adhesion molecule-1-dependent and -independent binding J Immunol 146 2 592 598 1:CAS:528:DyaK3MXht1Sjsrs%3D 1702807
41. H Udono PK Srivastava 1993 Heat-shock protein-70 associated peptides elicit specific cancer immunity J Exp Med 178 1391 1396 10.1084/jem.178.4.1391 1:CAS:528:DyaK3sXlsFOru7w%3D 8376942
42. XY Wang L Kazim EA Repasky JR Subjeck 2001 Characterization of heat shock protein 110 and glucose-regulated protein 170 as cancer vaccines and the effect of fever-range hyperthermia on vaccine activity J Immunol 166 490 497 1:CAS:528:DC%2BD3MXis1egtQ%3D%3D 11123328
43. XP Wang GZ Liu AL Song HY Li Y Liu 2004 Antitumor immunity induced by DNA vaccine encoding alpha-fetoprotein/heat shock protein 70 World J Gastroenterol 10 21 3197 3200 1:CAS:528:DC%2BD2cXhtVWrsrfI 15457574
44. WZ Wei WP Shi A Galy D Lichlyter S Hernandez B Groner, et al. 1999 Protection against mammary tumor growth by vaccination with full-length, modified human ErbB-2 DNA Int J Cancer 81 5 748 754 10.1002/(SICI)1097- 0215(19990531)81:5<748::AID-IJC14>3.0.CO;2-6 1:CAS:528:DyaK1MXjtF2ktL0%3D 10328228
45. A Worschech M Kmieciak KL Knutson HD Bear AA Szalay E Wang, et al. 2008 Signatures associated with rejection or recurrence in HER-2/neu-positive mammary tumors Cancer Res 68 7 2436 2446 10.1158/0008-5472.CAN-07-6822 1:CAS:528:DC%2BD1cXktV2js7o%3D 18381452
46. J Ye GS Chen HP Song ZS Li YY Huang P Qu YJ Sun XM Zhang YF Sui 2004 Heat shock protein 70 / MAGE-1 tumor vaccine can enhance the potency of MAGE-1-specific cellular immune responses in vivo Cancer Immunol Immunother 53 9 825 834 10.1007/s00262-004-0536-6 1:CAS:528:DC%2BD2cXmt1KrtLo%3D 15127237
47. I Yoshino GE Peoples PS Goedegebuure R Maziarz TJ Eberlein 1994 Association of HER2/neu expression with sensitivity to tumor-specific CTL in human ovarian cancer J Immunol 152 5 2393 2400 1:CAS:528:DyaK2cXisVajs70%3D 8133050
48. H Zhang W Huang 2006 Fusion proteins of Hsp70 with tumor-associated antigen acting as a potent tumor vaccine and the C-terminal peptide-binding domain of Hsp70 being essential in inducing antigen-independent anti-tumor response in vivo Cell Stress Chaperones 11 3 216 226 10.1379/CSC-191R.1 1:CAS:528:DC%2BD28XhtVOnsrvI 17009594
49. X Zhang C Yu J Zhao L Fu S Yi S Liu, et al. 2007 Vaccination with a DNA vaccine based on human PSCA and HSP70 adjuvant enhances the antigen-specific CD8+ T-cell response and inhibits the PSCA+ tumors growth in mice J Gene Med 9 8 715 726 10.1002/jgm.1067 1:CAS:528:DC%2BD2sXhtVKgsbfJ 17595048